Key Highlights:

  • Ping An Biomedical shares fell 11.19% to $4.76 on Friday, October 23, 2026.
  • A 1-for-40 reverse split took effect October 23, cutting Class A shares from about 112.9 million to 2.8 million.
  • The company signed a letter of intent on October 22 to buy three tumor cell-related patents for $2 million to $2.5 million.
  • Fiscal 2025 revenue fell 61.03% to 34.15 million yuan from 87.62 million yuan.
  • The fiscal 2025 net loss was 12.83 million yuan.

Ping An Biomedical Stock: Why Is the Penny Stock Down 11% Despite the Patent Deal?

Ping An Biomedical (NASDAQ:PASW) shares fell 11.19% to $4.76 on Friday, October 23, 2026, from a prior split-adjusted close of about $5.36 (calculated). It was the first session of trading after a 1-for-40 reverse stock split took effect, which means the quoted price reflects the new share count.

The company announced the split on October 21 and followed on October 22 with a letter of intent to acquire three patents. The company has not announced a separate catalyst for Friday's decline.

Reverse Split Details: What Changed for Shareholders on October 23?

Every 40 Class A and Class B ordinary shares were combined into one share of the same class. Class A shares outstanding fell from about 112.9 million to about 2.8 million, and Class B shares fell from about 12.3 million to about 306,250.

Combined shares of roughly 3.13 million (calculated) put the equity value near $14.9 million at $4.76 (calculated). Par value rose from $0.0000625 to $0.0025 per share, and the new CUSIP for Class A shares is G5880S139.

The company's release did not state a reason for the split. The company received a Nasdaq minimum bid price deficiency letter in late November 2025, according to filings.

Patent Acquisition: What Is Ping An Biomedical Buying?

The letter of intent covers three tumor cell-related medical technology patents. They address oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies.

The consideration is $2 million to $2.5 million. The company signed the letter with Future Biotechnology Group.

The deal remains at the letter-of-intent stage. Completion depends on due diligence, a definitive agreement and regulatory and contractual requirements, and the company said there is no assurance the transaction will close.

Financial Context: How Is the Underlying Business Performing?

Ping An Biomedical describes itself as a supply chain management provider in the apparel industry that is also focused on healthcare and biomedical technology solutions. It was formerly named Majestic Ideal Holdings, and its initial public offering closed in July 2025.

Fiscal 2025 revenue fell 61.03% to 34.15 million yuan from 87.62 million yuan, and the net loss was 12.83 million yuan.

In January 2026, the company announced a strategic investment relationship with Future Biotechnology Group, including a non-binding memorandum for an initial $30 million investment. On July 22, 2026, it signed a cooperation agreement with Yuan Sheng Mei Yan targeting 500 million yuan in sales over three years.

What to Watch Next: Will the Patent Letter of Intent Become a Definitive Deal?

The takeaway is that the stock fell in its first post-split session despite a new oncology strategy announcement, while the revenue base has shrunk. The next dated catalyst is the signing of a definitive patent acquisition agreement, for which no date has been given. Its Nasdaq bid price status is the other item to follow.

Shares fell 11.19% to $4.76 in the first session after a 1-for-40 reverse split, and the company has not announced a separate catalyst.

Three tumor cell-related patents covering oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies, for $2 million to $2.5 million.

About 2.8 million Class A shares and 306,250 Class B shares.